Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 6.64%, which has investors questioning if this is right time ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

in women in the later stages of epithelial ovarian, fallopian tube or primary peritoneal cancer who have received two or more lines of platinum chemotherapy. The US biotech said that Rubraca ...

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...